In the latest in a growing trend of pharma reshuffling moves in Asia, Marubeni Corporation is absorbing Sumitomo Pharma’s ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced 11 presentations will be shared at the American Academy of Neurology (AAN) 2025 Annual Meeting, taking place April 5-9 in San Diego, CA, and ...

"These findings help build upon our understanding of edaravone's potential effects in ALS," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. "By modulating TDP-43 ...

Bain Capital is in talks to acquire Mitsubishi Chemical Group’s pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said, a transaction that could ...

Tanabe Pharma is headquartered in Doshomachi, Osaka, and focuses on several priority therapeutic areas, including immunology ...

In its third-quarter results update, the company confirmed that it is halting further development of fasinumab, an NGF drug partnered with Teva and Mitsubishi Tanabe Pharma that was in phase 3 ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare ...

Edaravone may exert its neuroprotective effects in ALS by also correcting the abnormal localization of TDP-43, a key ...

Mitsubishi Tanabe Pharma Corporation isn’t backing away from the complex field of gene therapies — it’s investing in new cutting-edge projects on critical limb ischaemia and haemophilia B ...

TOKYO -- About 90% of patients with "obesity disease" in Japan perceive the medical condition as a personal responsibility, according to an awareness survey conducted by pharmaceutical firms, though ...